FUNDED by the US Food
and Drug Administration (FDA)
and Pfizer, three studies have
demonstrated the ability of
Heracles Pharma’s very low nicotine
tobacco, X-22 to satisfy a smoker’s
craving for cigarettes while
separating the act of smoking from
the rapid delivery of nicotine.
The company is seeking a strategic
pharmaceutical partner to fund a
final Phase III clinical study to help
in its application to the FDA for
approval of X-22 as a prescription based
smoking cessation aid.
X-22 cigarettes have 95% less
nicotine than regular cigarettes, the
company claims.
See more at heraclespharma.com.The above article was sent to subscribers in Pharmacy Daily's issue from 26 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 May 16
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.